Aimmune confirms $2B Nestle acquisition

On Monday, Aimmune Therapeutics announced that it had agreed to Nestle’s $2 billion dollar acquisition. Yahoo Finance’s Anjalee Khemlani sat down with Jayson Dallas, Aimmune’s CEO, to speak about the acquisition and about the peanut allergy treatment development. …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.